Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma

Abstract

A combination of intravenous cyclophosphamide and vincristine (Oncovin) and oral prednisone (COP) was given every 2 weeks to 262 patients with disseminated Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma, and follicular lymphoma. A complete remission was produced in 36% of patients with Hodgkin's disease, 50% of patients with lymphosarcoma, and 39% of patients with reticulum cell sarcoma. These remission rates are significantly superior to those produced by single agents. Patients who achieved a complete remission were randomly allocated to monthly COP (maintained remission) or to no treatment (unmaintained remission). The median duration of maintained remission was longer than unmaintained remission for Hodgkin's disease (42 weeks vs. 19 weeks) and lymphosarcoma (49 weeks vs. 21 weeks) but not for reticulum cell sarcoma (24 weeks vs. 25 weeks). The duration of remission for patients with little or no prior therapy was compared to that for patients in a similar study in which single agents were used.4 For lymphosarcoma and reticulum cell sarcoma, remissions maintained with COP were longer than remissions maintained with cyclophosphamide. For Hodgkin's disease and lymphosarcoma, unmaintained remissions after COP induction were longer than after single agent induction. All parameters of response, that is, complete remission rate, duration of remission, and survival were adversely affected by major prior treatment with radiotherapy and chemotherapy. The initial response to treatment correlated positively with survival. The survival of patients with lymphosarcoma or reticulum cell sarcoma receiving COP treatment was significantly superior to a comparable group of patients treated sequentially with single agents.

Long-Term Results in Patients with Low-Grade Nodular Non-Hodgkin'S Lymphoma A Randomized Trial Comparing Chemotherapy Plus Radiotherapy with Chemotherapy Alone

“…The CVP regimen has been reported to be useful in patients with nodular lymphoma (13). However, doxorubicin-containing regimens seem to be superior to CVP in terms of CR and RFS (9, 10) but their toxicity is also more pronounced and it is recommended to use doxorubicin in patients over 60 years of age with great caution.…”

Promising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions

“…In 1966 the chemotherapy regimen of cyclophosphamide, hydroxyldaunorubicin, vincristine and prednisone (CHOP) was introduced to manage lymphoma. This regimen improved the response rates previously achieved by single chemotherapeutic regimens from 50% to 69% as well as providing superior survival (2–6). Numerous efforts were made over prior decades to improve on the results obtained with CHOP, including complicated multi-drug regimens such as MACOP-B and COPLAM, unfortunately with no success.…”

Involvement of the ileocaecal region by non-Hodgkin's lymphoma in adults: clinical features and results of treatment

“…These were CHOP (Armitage et al, 1982), CHOP-PEPA (Mead et al, 1987), CVP (Luce et al, 1971) and the Southampton NH4 protocol (etoposide 150 mgm 2i.v. day 1, doxorubicin 35 mgm 2i.v.…”